Mitchell P McInerney1, Irene Volitakis2, Ashley I Bush2, William A Banks3,4, Jennifer L Short5, Joseph A Nicolazzo6. 1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences,, Monash University,, 381 Royal Parade, Parkville, VIC,, 3052, Australia. 2. The Florey Institute of Neuroscience and Mental Health,, Parkville, VIC, Australia. 3. Division of Gerontology and Geriatric Medicine, Department of Medicine,, University of Washington School of Medicine, Seattle, Washington,, USA. 4. Geriatrics Research Education and Clinical Center,, Veterans Affairs Puget Sound Health Care System,, Seattle, Washington,, USA. 5. Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University,, Parkville, VIC,, Australia. 6. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences,, Monash University,, 381 Royal Parade, Parkville, VIC,, 3052, Australia. joseph.nicolazzo@monash.edu.
Abstract
PURPOSE: Biometals such as zinc and copper have been shown to affect tight junction expression and subsequently blood-brain barrier (BBB) integrity. Whether these biometals also influence the expression and function of BBB transporters such as P-glycoprotein (P-gp) however is currently unknown. METHODS: Using the immortalised human cerebral microvascular endothelial (hCMEC/D3) cell line, an in-cell western assay (alongside western blotting) assessed relative P-gp expression after treatment with the metal ionophore clioquinol and biometals zinc and copper. The fluorescent P-gp substrate rhodamine-123 was employed to observe functional modulation, and inductively coupled plasma mass spectrometry (ICP-MS) provided information on biometal trafficking. RESULTS: A 24-h treatment with clioquinol, zinc and copper (0.5, 0.5 and 0.1 μM) induced a significant upregulation of P-gp (1.7-fold) assessed by in-cell western and this was confirmed with western blotting (1.8-fold increase). This same treatment resulted in a 23% decrease in rhodamine-123 accumulation over a 1 h incubation. ICP-MS demonstrated that while t8his combination treatment had no effect on intracellular zinc concentrations, the treatment significantly enhanced bioavailable copper (4.6-fold). CONCLUSIONS: Enhanced delivery of copper to human brain microvascular endothelial cells is associated with enhanced expression and function of the important efflux pump P-gp, which may provide therapeutic opportunities for P-gp modulation.
PURPOSE: Biometals such as zinc and copper have been shown to affect tight junction expression and subsequently blood-brain barrier (BBB) integrity. Whether these biometals also influence the expression and function of BBB transporters such as P-glycoprotein (P-gp) however is currently unknown. METHODS: Using the immortalised human cerebral microvascular endothelial (hCMEC/D3) cell line, an in-cell western assay (alongside western blotting) assessed relative P-gp expression after treatment with the metal ionophore clioquinol and biometals zinc and copper. The fluorescent P-gp substrate rhodamine-123 was employed to observe functional modulation, and inductively coupled plasma mass spectrometry (ICP-MS) provided information on biometal trafficking. RESULTS: A 24-h treatment with clioquinol, zinc and copper (0.5, 0.5 and 0.1 μM) induced a significant upregulation of P-gp (1.7-fold) assessed by in-cell western and this was confirmed with western blotting (1.8-fold increase). This same treatment resulted in a 23% decrease in rhodamine-123 accumulation over a 1 h incubation. ICP-MS demonstrated that while t8his combination treatment had no effect on intracellular zinc concentrations, the treatment significantly enhanced bioavailable copper (4.6-fold). CONCLUSIONS: Enhanced delivery of copper to human brain microvascular endothelial cells is associated with enhanced expression and function of the important efflux pump P-gp, which may provide therapeutic opportunities for P-gp modulation.
Authors: M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: Anand K Deo; Soo Borson; Jeanne M Link; Karen Domino; Janet F Eary; Ban Ke; Todd L Richards; David A Mankoff; Satoshi Minoshima; Finbarr O'Sullivan; Sara Eyal; Peng Hsiao; Ken Maravilla; Jashvant D Unadkat Journal: J Nucl Med Date: 2014-05-19 Impact factor: 11.082
Authors: Jae Pyun; Lachlan E McInnes; Paul S Donnelly; Celeste Mawal; Ashley I Bush; Jennifer L Short; Joseph A Nicolazzo Journal: J Neurochem Date: 2022-04-09 Impact factor: 5.546